December 8th 2023
The approval marks isavuconazonium sulfate as the only granted azole antifungal therapy for pediatric individuals AI and IM that are as young as 1 years old.
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Cognitive Training Programs Have No Long-Term Benefit for Children Born Very Preterm
September 13th 2023Children born at 24- through 34-weeks’ gestation could have neurobehavioral problems and developmental dysfunctions, including language, executive function, attention, and behavioral disorders.
Read More